Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
2.500
+0.030 (1.21%)
At close: Jan 2, 2026, 4:00 PM EST
2.500
0.00 (0.00%)
Pre-market: Jan 5, 2026, 8:38 AM EST
Invivyd Revenue
Invivyd had revenue of $13.13M in the quarter ending September 30, 2025, with 41.17% growth. This brings the company's revenue in the last twelve months to $50.04M, up 332.71% year-over-year. In the year 2024, Invivyd had annual revenue of $25.38M.
Revenue (ttm)
$50.04M
Revenue Growth
+332.71%
P/S Ratio
6.62
Revenue / Employee
$500,390
Employees
100
Market Cap
582.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IVVD News
- 13 days ago - Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - GlobeNewsWire
- 13 days ago - Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - GlobeNewsWire
- 5 weeks ago - Invivyd to Participate at the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness - GlobeNewsWire
- 6 weeks ago - Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination - Seeking Alpha
- 6 weeks ago - Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 6 weeks ago - Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 6 weeks ago - Invivyd Announces Proposed Public Offering of Common Stock - GlobeNewsWire